biOasis Technologies Ord Shs V.BTI.H

MedImmune

[JDavenport]

There have been questions about MedImmune raised on this forum since 2014. Where did they go? Why haven't they done anything with Bioasis after having such studies that were so successful that they put the results in a scientific paper.

Why don't they love me no more?

I've been wondering why MedImmune hasn't been mentioned here in the almost two weeks since the Bioasis/Daiichi Sankyo relationships were revealed in Bioasis's recent filings.

Does nobody remember that MedImmune was owned by AstraZeneca (AZ) until AZ shut the company down in 2019? As a result, AZ would have very good, first hand knowledge of Bioasis and xB3.

And then, of course, AZ partnered up with Daiichi Sankyo (DS) in the $6.9 billion Enhertu deal. And AZ claims to like conjugates.

And now Daichi Sankyo and Bioasis are buddies.

So, in the corner of the lab, is AZ watching what DS is doing with xB3? Is AZ involved? Is DS a proxy for AZ?

AZ probably knows more about xB3 than any other company. I don't know if they're involved in this latest stuff but we'd best get it on the record just in case. I don't believe a lot in coicidences in the secret worlds of drug development.

In the end, maybe we will get an answer to "What ever happened to MedImmune?"

Just speculating...

jd

[JDavenport]

About my earlier MedImmune post I wanted to mention that it's possible that Daiichi Sankyo could establish the relationship with Bioasis independently of AstraZeneca, without consulting them. I would suggest, though, that it's more likely that Daiichi Sankyo would have informed AstraZeneca, especially if any form of trastuzumab were to be involved in the Bioasis/Daiichi Sankyo

[InspiredTom]

Hi John, thanks for connecting the dots on the AZ / DS / Medimmune relationships. The partnership base is impressive, fun times ahead! Tom

[JDavenport]

Thanks, Tom, but don't take it all to the bank. The relationships, or maybe just the connections, are there, but until announcements are made, there can be no certainty. Sometimes corporate executives are too cute by half. Sometimes they think they're the smartest people in the room. They can think that nobody can figure things out. But, on the other hand, they can drop hints that are